A three‐gene leukaemic stem cell signature score is robustly prognostic in chronic myelomonocytic leukaemia-Reference-Cited by-同舟云学术

A three‐gene leukaemic stem cell signature score is robustly prognostic in chronic myelomonocytic leukaemia

Published:2023-02-06 Issue:2 Volume:201 Page:302-307
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Wang Yu‐Hung¹²³^ORCID,Yao Chi‐Yuan²⁴^ORCID,Lin Chien‐Chin²⁴^ORCID,Gurashi Kristian¹,Amaral Fabio M. R.³,Bossenbroek Hasse¹,Jerez Andres⁵^ORCID,Somervaille Tim C. P.³,Binder Moritz⁶^ORCID,Patnaik Mrinal M.⁶,Hou Hsin‐An²,Chou Wen‐Chien²⁴^ORCID,Batta Kiran¹,Wiseman Daniel H.¹^ORCID,Tien Hwei‐Fang²⁷

Affiliation:

1. Division of Cancer Sciences The University of Manchester Manchester UK

2. Division of Hematology National Taiwan University Hospital Taipei Taiwan

3. Leukaemia Biology Laboratory Cancer Research UK Manchester Institute Manchester UK

4. Department of Laboratory Medicine National Taiwan University Hospital Taipei Taiwan

5. Haematology Department Hospital Morales Meseguer Murcia Spain

6. Division of Hematology, Department of Internal Medicine Mayo Clinic Rochester Minnesota USA

7. Department of Internal Medicine Fra‐Eastern Memorial Hospital New Taipei City Taiwan

Abstract

SummaryLeukaemic stem cell (LSC) gene expression has recently been linked to prognosis in patients with acute myeloid leukaemia (17‐gene LSC score, LSC‐17) and myelodysplastic syndromes. Although chronic myelomonocytic leukaemia (CMML) is regarded as a stem cell disorder, the clinical and biological impact of LSCs on CMML patients remains elusive. Making use of multiple independent validation cohorts, we here describe a concise three‐gene expression signature (LSC‐3, derived from the LSC‐17 score) as an independent and robust prognostic factor for leukaemia‐free and overall survival in CMML. We propose that LSC‐3 could be used to supplement existing risk stratification systems, to improve prognostic performance and guide management decisions.

Funder

Ministry of Health and Welfare

Ministry of Science and Technology, Taiwan

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.18681

Reference32 articles.

1. A 17-gene stemness score for rapid determination of risk in acute leukaemia

2. A 4-gene leukemic stem cell score can independently predict the prognosis of myelodysplastic syndrome patients

3. Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management

4. When clinical heterogeneity exceeds genetic heterogeneity: thinking outside the genomic box in chronic myelomonocytic leukemia

5. Chronic myelomonocytic leukaemia stem cell transcriptomes anticipate disease morphology and outcome